The Mid-Atlantic Region

Home to nearly 3,600 biotech companies, the mid-Atlantic region (MD, VA, NC) is the industry epicenter of R&D, capital and policy.  Mid-Atlantic Bio’s proximity to the US government, federal labs, commercial research and development, academic centers of excellence and a growing investment community, make it a uniquely valuable venue for those in the life sciences community. Here are some statistics of interest about the Mid-Atlantic region (data: 2010 BIO/Battelle Report):

  • Nearly 3,600 bioscience companies which is about 8% of the US market.
  • More than 106,000 jobs, or 7% of the US bioscience workforce.
  • More than $3.5 billion is bioscience R&D, accounting for about 11% of total bioscience R&D in the US.
  • This region receives about 10% of all NIH funding in the US, totaling more than $2.7 billion.
  • Maryland, Virginia and North Carolina account for more than 35% of all clinical trials conducted in the US.

The addition of North Carolina in 2012 to the Mid-Atlantic Bio geography solidifies the conference’s position as the leading regional life-sciences event.  Mid-Atlantic Bio strategic partners include:  the Virginia Biotechnology Association (VABIO), Tech Council of Maryland (TCM), and Mid-Atlantic Venture Association (MAVA). New in 2012 is the addition of the North Carolina Biotechnology Center as a Strategic Partner.

The expanded geographic footprint offers the potential to increase access to key stakeholders and amplify our voice as one region.  But, members of our industry – and our region – must attend; for only through widespread participation can the critical mass be reached to maximize this center-stage opportunity:

Demonstrate the value biotechnology and impact of the Mid-Atlantic region

  • Promote sound public policy
  • Access investment capital and potential partners
  • Accelerate business development
  • Showcase the latest innovation